TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PICC Asymptomatic Thrombosis Study: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is indicated for a medically necessary PICC for therapeutic delivery medication~2. Patient is eligible to receive a single lumen PICC~3. Patient is an adult who is prescribed a PICC line~4. Patient's expected duration of treatment requiring a PICC for a minimum of 16 days post device implantation~5. Patient understands and is willing to comply with all study requirements and has voluntarily signed the Informed Consent Form (ICF).~Exclusion Criteria:~1. Is pregnant, lactating, or is planning to become pregnant during the time of the study~2. Has been previously enrolled in this post market clinical evaluation, or is participating in another clinical study that is contraindicative to the treatment or outcomes of this investigation~3. Venous thrombosis in any portion of the vein to be catheterized~4. Conditions that impede venous return from the extremity such as paralysis or lymphedema after mastectomy~5. Orthopedic or neurological conditions affecting the extremity~6. Anticipation or presence of dialysis grafts or other intraluminal devices, including pacemakers, within a month of patient enrollment start~7. Patients who are on anticoagulation therapy prior to the study (10-14 days). Note: (If patients are placed on anticoagulation (low dose) therapy while hospitalized, these patients are allowed.)~8. Patient has relinquished control of care to a guardian and/or facility~9. Patient has any significant medical or physical condition that, in the opinion of the PI, would make the subject unsuitable for participation in the post market clinical evaluation~10. Inability to complete the protocol in the opinion of the clinical staff due to safety or other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydrophilic BioMaterial (Type: ACTIVE_COMPARATOR): Hydrophilic BioMaterial- HydroPICC
- Thermoplastic Polyurethane (Type: ACTIVE_COMPARATOR): TPU- 4 French Single Lumen PowerPICC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Navigated Transcranial Magnetic Stimulation in Tumor Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 18 years of age and over.~* A brain tumor in the vicinity of the central region.~* Mild (BMRC grade 4/5) or no paresis.~* Obscured anatomy of the central region due to the mass effect/infiltrating growth pattern of the lesion~* Scheduled for elective surgery under general or local anesthesia.~* No other known brain abnormalities by history or by structural MRI.~* Mentally and physically able to undergo MR imaging (fMRI, DTI) and navigated TMS studies~* Signed informed consent form.~Exclusion Criteria:~* Implanted metallic parts of implanted electronic devices, including pacemakers, defibrillators, or implant medication pump.~* Pregnant or trying to become pregnant.~* History of alcohol abuse, illicit drug use or drug abuse or significant mental illness~* Hypertensive or hypotensive condition.~* Any condition that would prevent the subject from giving voluntary informed consent.~* An implanted brain stimulator.~* Aneurysm clip or other metal in the head (except mouth~* Enrolled or plans to enroll in an interventional trial during this study.~* Scalp wounds or infections.~* Claustrophobia precluding MRI~* Frequent seizures (\>1/week)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Navigated TMS examination (Type: None): 20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fenugreek on Milk Production

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mothers 2-12 weeks postpartum~* Mothers with term infants 37 weeks gestation or older~* Mothers with poor milk supply documented by professional lactation consultants~* Mothers whose milk supply is less than 600 cc per 24 hours~* Mothers who agree not to breastfeed or provide their milk to their infants during this study~Exclusion Criteria:~* Mothers with documented mastitis~* Mothers with breast engorgement~* Mothers with inverted nipples~* Maternal BMI greater than 35~* Mothers currently consuming Reglan, Domperidone or other drugs/herbals used to induce milk production~* Mothers who are clinically ill or hospitalized, or taking the following medications:~  1. Diuretics~ 2. Pseudoephedrine~ 3. Anticholinergics~ 4. Warfarin or any anticoagulant~ 5. An estrogen-containing birth control pill~* Mothers with Diabetes mellitus~* Mothers who have had breast surgery that could alter milk synthesis or production~* Mothers diagnosed with Polycystic ovary syndrome~* Mothers with tubular breasts or breasts with insufficient glandular tissue~* Mothers diagnosed with Asthma or atopic disease~* Mothers who are known to be allergic to peanuts or soybeans~* Mothers who are pregnant~* Mothers whose milk supply per 24 hours exceeds 600 mL~* Mothers with Obstetrical evaluation recommending exclusion

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Fenugreek category 1 (Type: EXPERIMENTAL): receive fenugreek
- Placebo Category 2 (Type: PLACEBO_COMPARATOR): receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men older than 18 years~* Diabetes mellitus type 2 defined according to the criteria of the American Diabetes Association Arterial hypertension defined according to the criteria of the Joint National Committtees (JNC 7)~* Given informed consent~Exclusion Criteria:~* Serve heart failure~* Serve aortic valve stenosis or hypertrophy obstructive cardiomyopathy~* Relevant cardiac arrhythmias~* Acute myocardial infarction within the last 4 weeks~* renal failure~* bilateral renal artery stenosis~* liver diseases~* primary hyperaldosteronism~* orthostatic hypotension (systolic blood pressure \<100mmHg)~* hypokalemia, hyponatremia, hypercalcemia, symptomatic hyperuricemia~* inflammatory disease~* malignant disease~* previous intolerance to AT1 receptor antagonists and/or sulfonamides~* current therapy with insulin sensitizer~* current therapy with digoxin~* known abuse of alcohol or drugs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): treatment with 80 mg Telmisartan per day for 30 days
- B (Type: ACTIVE_COMPARATOR): treatment with 20mg Telmisartan per day for 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Bispectral Index (BIS) Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 years of age~* Written informed consent from relatives~* Clinically stable~* Mechanically ventilated \< 2days~* Require sedation and expected to be given propofol~Exclusion Criteria:~* Recent injury or other pathologic condition of the esophagus~* Major bronchopleural fistula~* History of liver failure~* History of renal failure~* History of major neuromuscular disease~* Multiple trauma~* Upper motor nerve injury~* Hypersensitivity to propofol~* Recent gastrointestinal surgery~* Patients with a diagnosed or suspected condition that may give false results in BIS monitoring.~* Tracheostomized patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BIS 70 (Type: ACTIVE_COMPARATOR): BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
- BIS 50 (Type: ACTIVE_COMPARATOR): BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)
- BIS 35 (Type: ACTIVE_COMPARATOR): BIS levels of 35 will be targeted (low frequency EEG activity)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone in Poor Responders to IVF Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with prior poor response(s) to ovarian stimulation for IVF or ICSI. Poor response is defined as a history of producing fewer than four follicles ≥14 mm in diameter during previous COS cycles where FSH or HMG was used from cycle start at a daily dose of ≥450 IU~* Age ≤ 45 years~* Baseline blood labs, measured within previous month, show fasting blood glucose \<6.1 mmol/L and TSH ≤ 5.5 mU/L~* Early follicular phase (Day 2 or Day 3) serum FSH, evaluated in the preceding 6 months~* Subject willing and able to give informed consent~Exclusion Criteria:~* Concurrently enrolled in any other clinical trial~* Previous participation in this study~* Using GnRH agonist in COS protocol~* Any prior early follicular phase serum FSH level ≥12 IU/L~* Use of any of the following is contraindicated or inappropriate: GH, Cetrotide®, FSH, LH or hCG~* Used OCP within the prior month~* Pregnant or lactating~* Untreated hydrosalpinx~* Tobacco smoker~* Diabetic or otherwise at risk of gestational diabetes~* BMI \> 38 kg/m2~* Poorly controlled thyroid disease~* Known cancer or prior history of malignancies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- No Growth Hormone Supplementation (Type: ACTIVE_COMPARATOR): None
- Luteal Growth Hormone Start (Type: EXPERIMENTAL): Growth hormone starting in the luteal phase of the previous menstrual cycle.
- Follicular Growth Hormone Start (Type: EXPERIMENTAL): Starting growth hormone during the follicular phase of the prior menstrual cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented HIV-1 infection~* For the first 11 subjects (Panel A), screening plasma HIV-1 viral load is =10000 copies/mL and \<100000 copies/mL~* For the second set of 13 patients (Panel B), plasma HIV-1 viral load is =20000 copies/mL and \<500000 copies/mL~* Patients with CD4+ cell count above 100 cells/µl~* Patients have voluntarily signed the ICF~* Patients can comply with the protocol requirements~* Patient's general medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.~Exclusion Criteria:~* Presence of any currently active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with some exceptions~* Previous or current use of antiretroviral (ARVs/anti-HIV drugs) (including both investigational as well as commercially available ARVs indicated for the treatment of HIV-infection and ARVs for treatment of hepatitis B infection with anti-HIV activity (e.g., adefovir)~* Having one of protocol listed 1 PI, NRTI, or NNRTI resistance associated mutation at screening~* Patients with primary HIV infection~* Female patients of childbearing potential without use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period~* Any active clinically significant disease (e.g., abnormal heart function, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that are expected to compromise the patient's safety or outcome in the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccine Post Allogeneic Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient Population~  * HSCT recipients who are greater than 60 days post transplant.~ * Age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant~ * Show neutrophil recovery, platelet count \> 50,000/mm3 (may be transfused), no known disease relapse~ * No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~ * No flu vaccine in previous 4 months, no Campath in previous 6 months, no intravenous immune globulin (IVIG) in previous 3 months~* Controls:~  * Age 18 to 50 years~ * No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~ * No flu vaccine in previous 4 months

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Participants Receiving 1 Dose of Vaccine (Type: ACTIVE_COMPARATOR): Control group participants (healthy volunteers):~* Age 18 to 50 years~* No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~* No flu vaccine in previous 4 months~and/or HSCT recipients who are greater than 60 days post transplant.
- Participants Receiving 2 Doses of Vaccine (Type: ACTIVE_COMPARATOR): Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nasal High Flow Therapy for the Treatment of Respiratory Insufficiencies During Sleep

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women aged ≥ 18 years~* Heart Failure from ischemic or non-ischemic dilated cardiomyopathy for ≥ 6 months~* Left ventricular systolic dysfunction (LVEF ≤45% by echocardiography performed within 3 months of the screening visit, or if not within 3 months, a justification provided by the cardiologist for why a repeat echocardiography is not required, for example, because the subject's condition has remained stable since their echocardiography). All echocardiography must be within a maximum of 1 year of the screening visit.~* New York Heart Association Class II or III after optimization of medical therapy~* Stable Clinical Status on stable optimal medical therapy for ≥ 1 month before entry~Exclusion Criteria:~* Unstable angina~* Myocardial infarction within the last 12 months~* Cardiac surgery within the previous 6 months~* Pregnancy~* Unwilling or unable to provide informed consent~* Uncontrolled arrhythmias~* Severe valvular heart disease~* Current/prior use of mechanical ventilation (including CPAP). At the investigator's discretion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic PSG/PG, PSG w. nasal high flow therapy (Type: EXPERIMENTAL): All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
1. Patients must have histologically or cytologically confirmed non-small cell lung cancer.~2. Patients must be suitable for palliative radiation therapy as per institutional standards.~3. Stage IIB, III or IV (patients off steroids with treated, stable brain metastases are eligible).~4. Patients may be symptomatic or asymptomatic from disease~5. Age \>18 years~6. ECOG 0-1-2~7. Patients who received previous chemotherapy are allowed~8. Haemoglobin \>9g/dL (blood transfusion to increase Hb level is acceptable)~9. Stage II/III patients must be considered unsuitable for radical (standard full dose curative intent) chemoradiation in the opinion of either the radiotherapist or medical oncologist.~10. Patients must have measurable disease in the planned radiation field.~11. Women of child-bearing potential and men must agree to use adequate contraception.~12. Ability to understand and the willingness to sign a written informed consent document~Exclusion criteria - Phase I and Phase II:~1. Patients receiving any other investigational agents~2. Previous treatment with anti-EGF-R drug(s)~3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to nimotuzumab or other agents used in study.~4. Prior thoracic radiotherapy for this condition~5. Prior chemotherapy within 4 weeks of enrolment~6. Lesions not suitable for radiotherapy~7. Patients with known sero positive HIV~8. Patients with uncontrolled hypercalcemia~9. Patients with progressive or untreated brain metastases or treated brain metastases but unable to discontinue steroids~10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, severe cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator~11. Pregnant or breast-feeding women~12. Any concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix; patients with other prior malignancies are eligible providing prior malignancy cannot be clinically confused with the diagnosis of NSCLC in the opinion of the treating oncologist; in particular, there should be no evidence of current disease activity with respect to the prior malignancy~13. Life expectancy of less than 8 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 200 mg dose
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with diagnosis of schizophrenia (diagnosed ≤ 35 years of age).~* Current treatment consisting exclusively of olanzapine, risperidone/paliperidone, quetiapine or aripiprazole monotherapy for at least 2 months.~Exclusion Criteria:~* Inpatient hospitalization within past 3 months.~* Residence at the current address \< 3 months due to any instability in the disease.~* Presence of depressive symptoms.~* Past history of clinically significant violent behavior.~* Substance dependence or abuse.~* Pregnant or breast-feeding women or women not protected by effective contraceptive method of birth control.~The investigator will evaluate whether there are other reasons why a patient may not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- AVE1625 dose level 1 (Type: EXPERIMENTAL): None
- AVE1625 dose level 2 (Type: EXPERIMENTAL): None
- AVE1625 dose level 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy